-
Novo Nordisk raises outlook fuelled by obesity drug demand
Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected quarterly profits as the Danish drugmaker races to boost output of its hugely popular weight-loss drug Wegovy and fend off competition from rival Eli Lilly.
-
A new form of mpox that may spread more easily found in Congo's biggest outbreak
-
FDA brings lab tests under federal oversight in bid to improve accuracy and safety
-
Denmark to restrict Ozempic, other GLP-1 drugs, to treat type 2 diabetes
-
Application in SC seeking medical expert panel to examine Covishield vaccine side effects
Advertisement
Advertisement